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Background: We have sought histological evidence, using TDP-43 and p62 immunohistochemistry, for the
presence of expansions in C9ORF72 among 200 patients with pathologically confirmed AD.
Results: We noted TDP-43 pathological changes in hippocampus and temporal cortex in 45 (22.5%) of these
patients, but did not detect any cases where p62 positive changes in hippocampus and cerebellum, considered
pathognomic for C9ORF72 expansions, were present.
Conclusion: We conclude that expansions in C9ORF72 associated with AD are a rare occurrence, and in those
instances in the literature where these have been reported, the presence of AD may in fact be coincidental and
unrelated to the expansion.
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Frontotemporal Lobar Degeneration (FTLD) is a clinical,
pathological and genetically heterogeneous condition.
The major clinical syndromes principally involve personality
and behavioural change (behavioural variant frontotemporal
dementia, or bvFTD) or language alterations of a fluent
(semantic dementia) or non-fluent (agrammatic aphasia)
nature [1]. All three syndromes can be accompanied by
Motor Neurone Disease (MND), though bvFTD and MND
is the most common combination. Histologically, about half
of cases have tau-based pathology, half have TDP-43-based
pathology, and about 5% have FUS-based pathology [2].
Importantly, around 40% of cases have a strong family
history of similar disease, irrespective of clinical or histo-
logical subtype, and associate with variations in three major
genes – mutations in tau (MAPT) [3] and progranulin
(GRN) [4,5], or a large hexanucleotide (GGGGCC) ex-
pansion in C9ORF72 [6-8].
The expansion in C9ORF72 occurs in the first intron
or the promoter region of the gene, depending upon the
transcript isoform in question, and can number up to as* Correspondence: david.mann@manchester.ac.uk
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reproduction in any medium, provided the ormany as 1500 repeats [6-8]. The expansion is found in
about one in every twelve patients with FTLD or MND,
making it the most common genetic causes of both
these disorders [6-8]. Pathologically, most cases of FTLD
bearing the expansion [6-12], like many non-mutational
cases of FTLD [2], show inclusion bodies within neurones
(NCI) and glial cells of the cerebral cortex and hippocam-
pus that contain the nuclear transcription factor, TDP-43,
and are said bear a TDP-43 histological subtype termed
FTLD-TDP type B (according to Mackenzie classification
[13]), compatible with a clinical diagnosis of FTD and
MND. Others, however, show a TDP-43 histological
type characterised by the presence of many short
neurites (DN) along with NCI within the outer layers
of the cerebral cortex, and are termed FTLD-TDP type
A [13]. Nonetheless, irrespective of TDP-43 histological
type, all patients with FTLD (and indeed those with MND)
reported to bear expansion in C9ORF72 also show a unique
pathology within the dentate gyrus granule cells and CA4
pyramidal cells of the hippocampus [9] and granule cells of
the cerebellum [9,10] characterised by NCI that are TDP-
43 negative, but immunoreactive to p62 protein [6-12].
Interestingly, expansions have been reported to occur
within patients with other neurodegenerative disorders, par-
ticularly Alzheimer’s disease (AD) ([14-18] but see [19,20]).al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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has been reported [14-18], there has been no pathological
confirmation of disease histology, and therefore the under-
lying condition in such cases could still be FTLD, though
presenting in an atypical way. Nonetheless, there do still ap-
pear to be some cases of clinically relevant and pathologic-
ally confirmed AD bearing expansions in C9ORF72 [16,17].
About 25-45% cases of AD also show (secondary) TDP-
43 pathological changes within the amygdala, hippocampus,
and sometimes also in neocortical regions [21-24], the
proportion of ‘positive’ cases seemingly being dependent
upon how extensively the brain is sampled [21] Cases
are frequently encountered where TDP-43 pathological
changes are confined to the amygdala, and consequently
such ‘incidental’ cases may be considered negative if this
region is not examined [21]. However, when the neocor-
tex and hippocampus are also involved, the histological
pattern usually resembles that of FTLD-TDP type A
[21,22]. In those cases of pathologically confirmed AD
where expansions are present [16,17] no TDP-43 or p62
immunostaining had apparently been performed. It is
therefore possible that cases of AD bearing expansions,
like those with FTLD or MND [6-12], should show p62
changes in the hippocampus and cerebellum, as well as
a widespread TDP-43 proteinopathy.
Given that p62 changes in the hippocampus and cere-
bellum might be pathognomic for expansions in C9ORF72
[9,11], we immunostained sections of temporal cortex
(with hippocampus) and cerebellum in 200 pathologically
confirmed cases of AD in order to ascertain to what
extent an expansion in C9ORF72 might be present in
AD, particularly in those cases with (extensive) TDP-
43 pathology, since it is possible that such cases, in the
context of a clinical picture resembling AD, might be
ones with undisclosed/unrecognised FTLD.
Methods
Brain tissues were available in the Manchester Brain
Bank from a series of 200 patients with pathologicallyTable 1 Details of the 7 previous studies investigating the pr
patients with Alzheimer’s disease
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[14] 904 11 0 (0)
[15] 1217 5 0 (5)
[16] 872 5 1 (4)
[17] 1184 11 3 (6)
[18] 342 6 0 (5)
[19] 568 0 0
[20] 424 0 0 (0)
Total 5511 38 4 (20)confirmed AD (96 with early onset AD, 104 with late
(ie after 65 years) onset AD. All brains had been
obtained with full ethical permission following consent by
the next of kin. Paraffin sections were cut (at a thickness
of 6 μm) from formalin fixed blocks of temporal cortex
(with hippocampus) and cerebellar cortex and immuno-
stained by routine methods, involving pressure cooking
for antigen retrieval, for TDP-43 [22], and p62-lck ligand
(rabbit polyclonal antibody (B D Biosciences, Oxford, UK)
1:100), employing a standard ABC Elite kit (Vector,
Burlingame, CA, USA) with DAB as chromagen [22].
Immunostained sections were assessed for presence of
TDP-43 pathological changes within the hippocampus
dentate gyrus, the entorhinal cortex/fusiform gyrus and
the inferior and middle temporal gyri [22]. P62 pathological
changes were sought within the dentate gyrus and CA2/3/4
regions of the hippocampus, and within the granule cell
layer of the cerebellum, as described previously by Al-Sarraj
et al. [9], and Boxer et al. [10], respectively. Positive cases
were defined where either TDP-43 positive, or p62 positive,
TDP-43 negative NCI, within either the cerebellum or
hippocampus could be clearly seen under low power
objective (X20) and the majority of high power fields
(x40) contained at least 2 NCI. Negative cases were either
completely devoid of TDP-43 or p62 immunostaining, or
showed only small amounts of apparently extracellular and
‘extraneous’ p62 positive particulate material in occasional
high power fields.
Results and discussion
Trading on the ‘tightly coupled’ association between p62
pathological changes in the hippocampus and cerebellum
and the possession of hexanucleotide repeat in C9ORF72 in
FTLD [6-12], we sought to determine, from a patho-
logical basis, whether such expansions might occur in
patients with histopathologically verified AD. Consequently,
we screened 200 cases of AD for widespread TDP-43
pathological changes in hippocampus and temporal lobe,
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bellum (granule cells). Forty five (22.5%) of the 200
cases of AD showed TDP-43 pathology mostly resembling
FTLD-TDP type A histology [13], within the dentate gyrus
granule cells and entorhinal cortex/fusiform gyrus, and
within layer II pyramidal cells of inferior and middle
temporal gyri (as described previously by us [22] and
others [21,23,24]). However, no p62 immunoreactive NCI
were seen within pyramidal cells of areas CA2/3/4, or
within dentate gyrus granule cells, of the hippocampus
[9], or within granule cells of the cerebellum [10], in any
of these 45 cases, or in any of those cases of AD not show-
ing TDP-43 pathology. Hence, we conclude that, even in
the absence of formal genetic analysis, none of the 200
cases of AD examined here would likely be carriers of
C9ORF72 expansion.
All previous studies have been based either, exclusively
on cohorts of patients with clinically diagnosed AD, or on
cohorts with clinical AD but with limited pathological
investigations in some expansion bearing, or non-bearing,
individuals [14-20] (see Table 1). Collectively, these 7
studies have investigated 5511 patients with clinically
diagnosed AD. A total of 38 patients were found to
bear expansions in C9ORF72. Of these, of further clinical
review, 24 were still considered to have AD, and this was
confirmed on pathology in 4 instances. Of the other 14
patients, 12 were considered to have FTLD on further
review of the clinical notes, and two had this diagnosis
confirmed on pathology. Hence, of all the 38 expansion
carriers disclosed in these studies, only 4 could be said to
have definite AD. Therefore, in the absence of pathological
confirmation of disease, it remains possible that many
of the remaining carriers of expansions in C9ORF72
with a clinical presentation compatible with AD could
actually represent phenocopies of FTLD. Nonetheless, it
does appear that there are still a few cases with an expan-
sion in C9ORF72 where AD has indeed been confirmed
pathologically either in the index patient, or within other
members of the families involved [16,17].
However, it is noted that, in these latter studies [16,17],
expansion bearing cases had not had a full histopathological
work up, including p62 and TDP-43 immunohistochemis-
try, in order either to confirm the expansion pathologically,
or to rule out coincident FTLD or other neurodegeneration.
Moreover, in at least 2/4 such cases, onset of disease had
occurred after 70 years of age [17], with both individuals
bearing Apolipoprotein E ε4 allele, one being homozygous
for this [17]. We have previously shown that the presence
of Alzheimer-type pathology, which may be sufficient in
some instances to meet pathological criteria for AD, can
occur in elderly cases of FTLD, especially those bearing
Apolipoprotein E ε4 allele [25], and particularly so within
unaffected regions of the posterior hemisphere [26]. It is
therefore possible that the occurrence of AD pathology inexpansion bearers in the aforementioned studies [16,17] is
entirely coincidental, and unrelated to the expansion.
Indeed, we have also shown that elderly subjects with
FTLD commonly present with an AD-like syndrome
[27]. Hence, it remains possible that in such individuals
with AD pathology, the expansion in C9ORF72 might in
fact may be responsible for directing an FTLD type of
process, which has not be disclosed, since apparently in
none of these studies had expansion carriers been inves-
tigated for these kinds of histological changes.
Conclusions
In conclusion, in the present study, we sought histological
evidence for the presence of expansions in C9ORF72
among 200 patients with pathologically confirmed AD,
but did not detect any cases where relevant tissue changes
were present. We conclude that expansions in C9ORF72
are a rare occurrence in AD, and in instances where these
do occur, the presence of AD may be coincidental and
unrelated to the expansion. Further investigations on such
cases to exclude the presence of an underlying FTLD
process driven by the expansion appear warranted.
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